Remove Innovation Remove Kidney Disease Remove Quality of Life
article thumbnail

Top 10 Cardiac Diagnosis Trends in 2024

GEMMS

In this article, we will explore the top 10 trends shaping the future of cardiovascular medicine, highlighting the innovative technologies and approaches that are revolutionizing the field. Genetic testing and DNA sequencing improve the accuracy of predicting heart disease risk.

article thumbnail

Bayer to Present New Investigational Heart Failure Data, Continued Portfolio Research in Chronic Kidney Disease at ACC.25

DAIC

25 include Efficacy and safety of finerenone across the spectrum of kidney risk in heart failure with mildly reduced or preserved ejection fraction during the session;"Innovations and Insights in Heart Failure With Preserved Ejection Fraction: Emerging Therapies, Biomarkers and Mechanistic Studies." Additional ACC.25

article thumbnail

Bayer to Present New Investigational Heart Failure Data, Continued Portfolio Research

DAIC

25 include Efficacy and safety of finerenone across the spectrum of kidney risk in heart failure with mildly reduced or preserved ejection fraction during the session;"Innovations and Insights in Heart Failure With Preserved Ejection Fraction: Emerging Therapies, Biomarkers and Mechanistic Studies." Additional ACC.25

article thumbnail

Creative Alliances in Cardiorenal Metabolic Management: A Game Changer (Part 1) 

Cardiometabolic Health Congress

These interconnected diseases pose a significant global health threat, with cardiovascular diseases alone accounting for one-third of all deaths worldwide , according to the World Health Organization. We need a comprehensive and innovative approach to cardiorenal metabolic management and risk reduction to address this challenge.

article thumbnail

5 Most-Cited Takeaways From the 19th Annual Cardiometabolic Health Congress (CMHC) 

Cardiometabolic Health Congress

What better way to join the fall festivities than by spotlighting key insights in cardiorenal metabolic medicine, primary prevention, and quality of life improvements shared at this year’s biggest U.S. cardiometabolic health CME/CE conference: the 19th Annual CMHC. In the U.S., SELECT Trial Results : Semaglutide 2.4

CME 103